Mounjaro vs Zepbound Price Comparison 2026: Same Drug, Very Different Bills

Mounjaro and Zepbound are the same medication — tirzepatide — made by Eli Lilly. The difference is what you'll pay, and that depends on your diagnosis and insurance.

If you're comparing Mounjaro and Zepbound, here's the most important thing to know upfront: they are pharmacologically identical. Both contain tirzepatide, a dual GLP-1/GIP receptor agonist. Same molecule, same manufacturer, same dosing schedule, same side effects, same weight loss outcomes. The only differences are the FDA-approved indication and, consequently, what you'll pay.

This guide focuses on the cost difference — because that's where the two brands diverge dramatically.

They're the Same Drug — So Why Two Brands?

Eli Lilly ran separate clinical trial programs for tirzepatide: the SURPASS trials for type 2 diabetes and the SURMOUNT trials for weight management. The FDA requires separate brand names for separate indications, so Mounjaro was approved for type 2 diabetes in 2022, and Zepbound was approved for chronic weight management (and later for obstructive sleep apnea) in 2023–2024.

This is the same setup as Ozempic/Wegovy — one molecule, two labels, two insurance paths. And just like with semaglutide, the insurance path is what determines your actual price.

Price Comparison: What You'll Actually Pay

The LillyDirect Advantage

The biggest cost differentiator in 2026 is Eli Lilly's LillyDirect program for Zepbound. Through this channel, you can get Zepbound single-dose vials at $499/month regardless of dose. Whether you're on the starter 2.5 mg dose or the maximum 15 mg, you pay the same flat rate.

Mounjaro has no equivalent cash-pay program from Eli Lilly. Without insurance, Mounjaro patients pay close to list price (~$1,069/month) at retail pharmacies. This makes Zepbound the clear winner for uninsured patients who want brand-name tirzepatide.

The trade-off: LillyDirect vials require you to draw your own dose with a syringe, rather than using the convenience of the KwikPen auto-injector. For most patients, this is a minor learning curve — your provider can walk you through the process — but it's worth knowing before you commit.

Which One Should You Ask For?

Since the medication is identical, your decision comes down to your diagnosis, insurance coverage, and access to savings programs.

Can You Switch Between Them?

Yes — switching is seamless because the active ingredient is identical. Your prescriber writes a new prescription for the other brand at your current dose. There's no adjustment period, no re-titration, and no difference in how the medication works. The most common reason patients switch is a change in insurance coverage or diagnosis status.

One important detail: pharmacies cannot substitute one for the other on their own, even though the molecule is the same. They have different NDC (National Drug Code) numbers, so your prescriber needs to specify which brand on the script.

What About Compounded Tirzepatide?

If both Mounjaro and Zepbound are out of your budget, compounded tirzepatide from telehealth providers typically runs $149–$399/month depending on dose. Compounded versions use the same active ingredient but are prepared by licensed compounding pharmacies rather than Eli Lilly.

At higher maintenance doses, the LillyDirect Zepbound vial program ($499/month flat) becomes competitive with compounded tirzepatide — while offering FDA-approved quality assurance. It's worth running the numbers for your specific dose before assuming compounded is always cheaper.